Baidu
map
CELL MOL IMMUNOL 润色咨询

Cellular & Molecular Immunology

出版年份:2004 年文章数:575 投稿命中率: 开通期刊会员,数据随心看

出版周期:Bimonthly 自引率:6.9% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2024-08-19 ms7000000083792829 来自澳门

    偏重的研究方向:免疫药理学
    经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2024-06-04 1217be29m97(暂无昵称) 来自重庆

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2024-07-19 ms2000000158560355 来自广东省

    投稿两周了,还在under consideration

    9

    展开9条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2024-07-15 ms7000000083792829 来自欧洲

    审稿速度:3.0 | 投稿命中率:5.0
    偏重的研究方向:免疫
    经验分享:投稿1周,送审,等待中

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2024-06-23 行走的 来自福建省

    请问送审也是显示under consideration吗?不显示under review?

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2024-06-03 145f8226m51暂无昵称 来自山东省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:免疫;炎症因子;免疫调节
    经验分享:已经见刊,效率非常高

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2022-04-28 146de754m00暂无昵称

    审稿速度:6.0 | 投稿命中率:5.0
    偏重的研究方向:免疫学
    经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂

    7

    展开7条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2024-01-27 ms8000000965566049 来自北京

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:无

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2023-05-21 侠胆医心 来自上海

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学
    经验分享:一、基本情况:
    CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。
    二、收录范围:
    CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:
    ·临床免疫学·比较免疫学·免疫生物学
    ·免疫遗传学·免疫学技术·免疫病理学
    ·免疫药理学·感染免疫学·神经免疫学
    ·移植免疫学·肿瘤免疫学·兽医免疫学
    三、发文量
    近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。
    四、影响因子
    CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。
    五、投稿费用:
    作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2221390, encodeId=0117222139070, content=偏重的研究方向:免疫药理学<br>经验分享:投稿两个周收到邮件送外审,现在审稿5个周了,没有任何消息,投稿系统状态还是under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Aug 19 20:34:03 CST 2024, time=2024-08-19, status=1, ipAttribution=澳门), GetPortalCommentsPageByObjectIdResponse(id=2208180, encodeId=3b0522081805d, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:第一次投稿3个星期外审回复,第二次投稿50多天外审还没有回复,处理稿件时间不定。且状态一直Manuscript Under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99ec2258493, createdName=1217be29m97(暂无昵称), createdTime=Tue Jun 04 08:55:29 CST 2024, time=2024-06-04, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2215784, encodeId=3a172215e8460, content=投稿两周了,还在under consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5f9391411, createdName=ms2000000158560355, createdTime=Fri Jul 19 18:49:43 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215129, encodeId=5f22221512993, content=审稿速度:3.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫<br>经验分享:投稿1周,送审,等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18846462112, createdName=ms7000000083792829, createdTime=Mon Jul 15 18:34:24 CST 2024, time=2024-07-15, status=1, ipAttribution=欧洲), GetPortalCommentsPageByObjectIdResponse(id=2211205, encodeId=b91f221120564, content=请问送审也是显示under consideration吗?不显示under review?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230123/3baa3de4a36849329951106301a558f5/640ed86936c34f80b292d32698f4c504.jpg, createdBy=60a42272848, createdName=行走的, createdTime=Sun Jun 23 08:46:37 CST 2024, time=2024-06-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2208080, encodeId=a09d2208080fb, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫;炎症因子;免疫调节<br>经验分享:已经见刊,效率非常高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9bdb5102224, createdName=145f8226m51暂无昵称, createdTime=Mon Jun 03 17:15:18 CST 2024, time=2024-06-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1215445, encodeId=a98e121544508, content=审稿速度:6.0 | 投稿命中率:5.0<br>偏重的研究方向:免疫学<br>经验分享:21年12月初投稿,第二天就送审了,但是网站不会变更状态,直到22年3月底收到了拒稿的消息,并没有宣传的审稿快国人友好,请大家慎重,国产杂志懂得都懂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1395, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ab1f5172980, createdName=146de754m00暂无昵称, createdTime=Thu Apr 28 20:45:48 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184240, encodeId=71092184240ac, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af039127698, createdName=ms8000000965566049, createdTime=Sat Jan 27 06:26:43 CST 2024, time=2024-01-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2138139, encodeId=3d372138139c0, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫药理学;临床免疫学;免疫遗传学<br>经验分享:一、基本情况:<br>CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>二、收录范围:<br>CMI涵盖了基础免疫学研究和临床应用,为我们了解宿主在体外和体内的免疫反应提供了最新的信息和进展。该期刊接收的文章范围包括但不限于:<br>·临床免疫学·比较免疫学·免疫生物学<br>·免疫遗传学·免疫学技术·免疫病理学<br>·免疫药理学·感染免疫学·神经免疫学<br>·移植免疫学·肿瘤免疫学·兽医免疫学<br>三、发文量<br>近五年CMI的发文量分别为77篇(2017),76篇(2018),75篇(2019),179篇(2020)和108篇(2021)。<br>四、影响因子<br>CMI近几年的影响因子逐年攀升:2017(7.551),2018(8.213),2019(8.484),2020(11.53)和2021(22.096)。继2020年影响因子一跃破10后,2022年的影响因子更是一举破20,达到了22.096。<br>五、投稿费用:<br>作者投稿CMI时可选择免费的传统非OA模式,也可以选择提交版面费的OA模式。选择OA模式后,被CMI接收的文章需要作者或其机构支付一笔文章出版费(APC)为4790美元,折合人民币大概33000人民币。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=146, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sun May 21 10:13:17 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144483, encodeId=ebad2144483e0, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫遗传;移植免疫;免疫调节<br>经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。<br>CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。<br>医学1区,免疫学1区,预计在今年影响因子可能还会增长。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 24 11:18:28 CST 2023, time=2023-06-24, status=1, ipAttribution=上海)]
    2023-06-24 侠胆医心 来自上海

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向:免疫遗传;移植免疫;免疫调节
    经验分享:CMI的第一届主编是我国免疫学界大牛周光炎教授,主要从事免疫遗传、免疫调节和移植免疫方面的研究,已于2009年卸任。现今是由中国工程院的曹雪涛院士和中国科学技术大学生命科学学院的田志刚教授担任共同主编,其余编辑也大多是国人或华侨。该刊目前仍保持着强劲的发展势头。
    CMI的审稿周期在两到三个月,有个别四个月才被接收,也有那种几天就被接收的,极速接收的那种大概率是CMI向作者的约稿吧。
    医学1区,免疫学1区,预计在今年影响因子可能还会增长。

    2

    展开2条回复
共71条页码: 1/8页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map